A test capable of confirming or ruling out Alzheimer’s disease has been validated and standardized. By measuring cerebrospinal fluid concentrations of two of the disease’s biochemical hallmarks — amyloid beta42 peptide and tau protein — the test also predicted whether a person’s mild cognitive impairment would convert to Alzheimer’s disease over time. The test accurately ruled out Alzheimer’s disease in 95.2 percent of the subjects.